Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance

Adaptive Biotechnologies CorpTrade
iShares iBoxx $ High Yield Corporate Bond ETFTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $24.96 (market cap $4.04B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.62. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.

ADPTHYG
Market Cap
$4.04B
Sector
HealthFixed Income
52-Week High
$25.45$81.32
52-Week Low
$12.30$78.72
Enterprise Value
$4.10B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.

Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.

iShares iBoxx $ High Yield Corporate Bond ETF

HYG, the iShares iBoxx $ High Yield Corporate Bond ETF, trades at $79.615, up 0.17% on the day. Technical indicators show a bearish trend with key support at $79 and resistance at $80. Recent news highlights bond market volatility amid inflation concerns and rising oil prices, while the ETF faces criticism for underperformance versus peers.

The outlook for HYG is cautious due to bearish technicals and macroeconomic headwinds like potential Fed rate hikes. Risks include high-yield credit exposure and inflation sensitivity, but the ETF's 6.5% dividend yield may attract income-focused investors amid broader bond market inflows.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About iShares iBoxx $ High Yield Corporate Bond ETF

HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.

Read more on HYG